Montenegro skin test and age of skin lesion as predictors of treatment failure in cutaneous leishmaniasis;Intensidade da intradermorreação de Montenegro e tempo de evolução da lesão como preditores de falha na resposta terapêutica da leishmaniose cutânea

Revista do Instituto de Medicina Tropical de Sao Paulo

Volumn 56, Issue 5, 2014, Pages 375-380

  Antonio, Liliane de Fátima ^a   Fagundes, Aline ^a   Oliveira, Raquel Vasconcellos Carvalhaes ^a   Pinto, Priscila Garcia ^a   Bedoya Pacheco, Sandro Javier ^a   Vasconcellos, ÉRica de Camargo Ferreira e ^a   Valete Rosalino, Maria CláUdia ^a,b   Lyra, Marcelo Rosandiski ^a   Passos, Sônia Regina Lambert ^a   Pimentel, Maria Inês Fernandes ^a   Schubach, Armando de Oliveira ^a,c  

^a Funda??o Oswaldo Cruz   (Brazil)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^c Researcher Level 1D of the National Council of Scientific and Technologic Development (CNPq)   (Brazil)

Author keywords

Cutaneous leishmaniasis; Skin tests; Treatment failure

Indexed keywords

MEGLUMINE ANTIMONATE; ANTIPROTOZOAL AGENT; MEGLUMINE; MEGLUMINE ANTIMONIATE; ORGANOMETALLIC COMPOUND;

ADOLESCENT; ADULT; AGE; ARTICLE; CASE CONTROL STUDY; CELLULAR IMMUNITY; CHILD; CHRONIC GRANULOMATOUS DISEASE; CONTROLLED STUDY; CULTURAL ANTHROPOLOGY; DATA ANALYSIS; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LEISHMANIN SKIN TEST; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MICROBIOLOGICAL EXAMINATION; OBSERVATIONAL STUDY; PARASITOLOGY; SCAR; SEROLOGY; SKIN DEFECT; SKIN LEISHMANIASIS; TREATMENT FAILURE; TREATMENT RESPONSE; FEMALE; INTRACUTANEOUS TEST; LEISHMANIASIS, CUTANEOUS; MIDDLE AGED; PRESCHOOL CHILD; PROCEDURES; RETROSPECTIVE STUDY; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIPROTOZOAL AGENTS; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INTRADERMAL TESTS; LEISHMANIASIS, CUTANEOUS; MALE; MEGLUMINE; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; RETROSPECTIVE STUDIES; TREATMENT FAILURE; YOUNG ADULT;

EID: 84907157232     PISSN: 00364665     EISSN: 16789946     Source Type: Journal    
DOI: 10.1590/S0036-46652014000500002     Document Type: Article

References (35)

1. Antígeno de Montenegro. Bula do antígeno. Paraná: Centro de Produção e Pesquisa de Imunobiológicos-CPPI; 2008. [cited 2011 Oct 17]; Available from: http://www.saude.pr.gov.br/arquivos/File/CPPI/bulas/montenegro.pdf
2. Bacellar O, Lessa H, Schriefer A, Machado P, Ribeiro de Jesus A, Dutra W, et al. Up-regulation of Th1-type responses in mucosal leishmaniasis patients. Infect Immun. 2002;70:6734-40.
3. Bearman JE, Kleinman H, Glyer VV, Lacroix OM. A study of variability in tuberculin test reading. Am Rev Respir Dis. 1964;90:913-9.
4. Ben Salah A, Louzir H, Chlif S, Mokni M, Zaatour A, Raouene M, et al. The predictive validity of naturally acquired delayed-type hypersensitivity to leishmanin in resistance to Leishmania major-associated cutaneous leishmaniasis. J Infect Dis. 2005;192:1981-7.
5. Brasil. Ministério da Saúde. Manual de vigilância da leishmaniose tegumentar cutânea. 3a ed. Brasília: Ministério da Saúde; 2010.
6. Bustamante MCFS, Pereira MJS, Schubach AO, Fonseca AH. Epidemiological profile of cutaneous leishmaniasis in an endemic region in the State of Rio de Janeiro, Brazil. Rev Bras Parasitol Vet. 2009;18:34-40.
7. Curti MCM, Silveira TGV, Arraes SMAA, Bertolini DA, Zanzarini PD, Venazzi EAS, et al. Epidemiological and clinical characteristics of cutaneous leishmaniasis and their relationship with the laboratory data, south of Brazil. Braz J Infect Dis. 2011;15:12-6.
8. DATASUS. Leishmaniose tegumentar americana: casos confirmados notificados no sistema de informação de agravos de notificação. Brasília: Ministério da Saúde/ SINAN; 2011. [cited 2011 Oct 17]. Available from: http://dtr2004.saude.gov.br/sinanweb/tabnet/dh?sinan/lta/bases/ltabr.def
9. De Luca PM, Mayrink W, Alves CR, Coutinho SG, Oliveira MP, Bertho AL, et al. Evaluation of the stability and immunogenicity of autoclaved and nonautoclaved preparations of a vaccine against American tegumentary leishmaniasis. Vaccine. 1999;17:1179-85.
10. De Luca PM, Mayrink W, Pinto JA, Coutinho SG, Santiago MA, Toledo VP, et al. A randomized double-blind placebo-controlled trial to evaluate the immunogenicity of a candidate vaccine against American tegumentary leishmaniasis. Acta Trop. 2001;80:251-60.
11. De Oliveira-Neto MP, Mattos MS, Perez MA, Da-Cruz AM, Fernandes O, Moreira J, et al. American tegumentary leishmaniasis (ATL) in Rio de Janeiro State, Brazil: main clinical and epidemiologic characteristics. Int J Dermatol. 2000;39:506-14.
12. Deps PD, Viana MC, Falqueto A, Dietze R. Avaliacão comparativa da eficácia e toxicidade do antimoniato de N-metil-glucamina e do estibogluconato de sódio BP88© no tratamento da leishmaniose cutânea localizada. Rev Soc Bras Med Trop. 2000;33:535-43.
13. Gontijo B, Carvalho MLR. Leishmaniose tegumentar americana. Rev Soc Bras Med Trop. 2003;36:71-80.
14. Machado P, Araújo C, Da Silva AT, Almeida RP, D’Oliveira Jr A, Bittencourt A, et al. Failure of early treatment of cutaneous leishmaniasis in preventing the development of an ulcer. Clin Infect Dis. 2002;34:E69-73.
15. Manzur A, Bari Au. Sensitivity of leishmanin skin test in patients of acute cutaneous leishmaniasis. Dermatol Online J. 2006;12:2.
16. Melo MN, Mayrink W, da Costa CA, Magalhaes PA, Dias M, Williams P, et al. Padronização do antígeno de Montenegro. Rev Inst Med Trop Sao Paulo. 1977;19:161-4.
17. Montenegro J. A cútis-reação na leishmaniose. Ann Fac Med Univ Sao Paulo. 1926;1:323-30.
18. Nogueira MF, Goto H, Sotto MN, Cucé LC. Cytokine profile in Montenegro skin test of patients with localized cutaneous and mucocutaneous leishmaniasis. Rev Inst Med Trop Sao Paulo. 2008;50:333-7.
19. Oliveira LF, Schubach AO, Martins MM, Passos SL, Oliveira RV, Marzochi MC, et al. Systematic review of the adverse effects of cutaneous leishmaniasis treatment in the New World. Acta Trop. 2011;118:87-96.
20. Oliveira-Neto MP, Schubach AO, Mattos M, Gonçalves-Costa SC, Pirmez C. A low-dose antimony treatment in 159 patients with American cutaneous leishmaniasis: extensive follow-up studies (up to 10 years). Am J Trop Med Hyg. 1997a;57:651-5.
21. Oliveira-Neto MP, Schubach AO, Mattos M, Gonçalves-Costa SC, Pirmez C. Treatment of American cutaneous leishmaniasis: a comparison between low dosage (5 mg/ kg/day) and high dosage (20 mg/kg/day) antimony regimens. Pathol Biol (Paris). 1997b;45:496-9.
22. Passos VM, Barreto SM, Romanha AJ, Krettli AU, Volpini AC, Lima e Costa MF. American cutaneous leishmaniasis: use of a skin test as a predictor of relapse after treatment. Bull World Health Organ. 2000;78:968-74.
23. Pessoa SB, Pestana BR. A intradermo-reação de Montenegro nas campanhas sanitárias contra a leishmaniose. Arq Hyg Saúde Publ. 1940;5:125-37.
24. Pirmez C, Yamamura M, Uyemura K, Paes-Oliveira M, Conceição-Silva F, Modlin RL. Cytokine patterns in the pathogenesis of human leishmaniasis. J Clin Invest. 1993;91:1390-5.
25. Reis LC, Brito MEF, Almeida EL, Félix SM, Medeiros ACR, Silva CJ, et al. Clinical, epidemiological and laboratory aspects of patients with American cutaneous leishmaniasis in the State of Pernambuco. Rev Soc Bras Med Trop. 2008;41:439-43.
26. Reis LC, Brito MEF, Souza MA, Medeiros ACR, Silva CJ, Luna CF, et al. Cellular immune response profile in patients with American tegumentary leishmaniasis prior and post chemotherapy treatment. J Clin Lab Anal. 2009;23:63-9.
27. Rodrigues AM, Hueb M, Santos TARR, Fontes CJF. Fatores associados ao insucesso do tratamento da leishmaniose cutânea com antimoniato de meglumina. Rev Soc Bras Med Trop. 2006;39:139-45.
28. Sassi A, Louzir H, Ben Salah A, Mokni M, Ben Osman A, Dellagi K. Leishmanin skin test lymphoproliferative responses and cytokine production after symptomatic or asymptomatic Leishmania major infection in Tunisia. Clin Exp Immunol. 1999;116:127-32.
29. Schubach AO, Marzochi KBF, Moreira JS, Schubach TMP, Araújo ML, Vale ACF, et al. Retrospective study of 151 patients with cutaneous leishmaniasis treated with meglumine antimoniate. Rev Soc Bras Med Trop. 2005;38:213-7.
30. Silva AF. Avaliação do teste intradérmico de Montenegro em populações militares do Brasil: positividade e resposta inespecífica. [dissertação]. Rio de Janeiro: Fundação Oswaldo Cruz, Instituto Oswaldo Cruz; 1999.
31. Silva AF. A reação intradérmica de Montenegro na clínica e na epidemiologia da leishmaniose tegumentar. [tese]. Rio de Janeiro: Fundação Oswaldo Cruz, Instituto Nacional de Controle de Qualidade em Saúde; 2007.
32. Stefanidou MP, Antoniou M, Koutsopoulos AV, Neofytou YT, Krasagakis K, Krüger-Krasagakis S, et al. A rare case of leishmaniasis recidiva cutis evolving for 31 years caused by Leishmania tropica. Int J Dermatol. 2008;47:588-9.
33. Teixeira AC, Paes MG, Guerra JO, Prata A, Silva-Vergara ML. Failure of both azithromycin and antimony to treat cutaneous leishmaniasis in Manaus, AM, Brazil. Rev Inst Med Trop Sao Paulo. 2008;50:157-60.
34. Unger A, O’Neal S, Machado PRL, Guimarães LH, Morgan DJ, Schriefer A, et al. Association of treatment of American cutaneous leishmaniasis prior to ulcer development with high rate of failure in northeastern Brazil. Am J Trop Med Hyg. 2009;80:574-9.
35. Weigle KA, Valderrama L, Arias AL, Santrich C, Saravia NG. Leishmanin skin test standardization and evaluation of safety, dose, storage, longevity of reaction and sensitization. Am J Trop Med Hyg. 1991;44:260-71.